Видео ютуба по тегу Medicines: Olaparib

Olaparib plus abiraterone could be a new first-line treatment option for mCRPC | Fred Saad
Olaparib plus abiraterone could be a new first-line treatment option for mCRPC | Fred Saad
Olaparib Maintenance for Recurrent Ovarian Cancer
Olaparib Maintenance for Recurrent Ovarian Cancer
The story of olaparib: a life-saving cancer drug
The story of olaparib: a life-saving cancer drug
Exploring the use of olaparib in advanced breast cancer
Exploring the use of olaparib in advanced breast cancer
7-year OS from SOLO1: sustained benefit with maintenance olaparib
7-year OS from SOLO1: sustained benefit with maintenance olaparib
Selecting patients to be treated with maintenance olaparib in the PAOLA-1 trial
Selecting patients to be treated with maintenance olaparib in the PAOLA-1 trial
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations
PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations
Olaparib in Ovarian Cancer
Olaparib in Ovarian Cancer
2020 In Review: Olaparib & Rucaparib, FDA Approval | Ask a Prostate Expert, Mark Scholz, MD
2020 In Review: Olaparib & Rucaparib, FDA Approval | Ask a Prostate Expert, Mark Scholz, MD
#ESMO21 Highlights on maintenance olaparib in ovarian cancer previously treated with PARPi
#ESMO21 Highlights on maintenance olaparib in ovarian cancer previously treated with PARPi
Using Olaparib in gBRCA1/2+ Breast Cancer
Using Olaparib in gBRCA1/2+ Breast Cancer
PARP Inhibitor Olaparib Exceeds Expectations in BRCA+ Pancreatic Cancer Management
PARP Inhibitor Olaparib Exceeds Expectations in BRCA+ Pancreatic Cancer Management
Maintenance Olaparib in Patients With Ovarian Cancer
Maintenance Olaparib in Patients With Ovarian Cancer
Reassuring Data: Olaparib Dose Reductions Have Minimal Effect
Reassuring Data: Olaparib Dose Reductions Have Minimal Effect
Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast Cancer
Dr. Tripathy on Impact of Olaparib Approval in BRCA-Positive Breast Cancer
Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer
Dr. Morgan on Olaparib for Metastatic Castration-Resistant Prostate Cancer
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer
Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer